A5047849583- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Pancreatitis Pathology and Treatment
- Neutropenia and Cancer Infections
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Cancer, Lipids, and Metabolism
- Prostate Cancer Treatment and Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
- Gallbladder and Bile Duct Disorders
- Vascular Tumors and Angiosarcomas
- Neuroblastoma Research and Treatments
- HER2/EGFR in Cancer Research
- Urinary Tract Infections Management
- Protein Degradation and Inhibitors
- Toxoplasma gondii Research Studies
- Thyroid Cancer Diagnosis and Treatment
Japanese Red Cross Kumamoto Hospital
2017-2025
National Cancer Center Hospital East
2015-2021
Abstract Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard regimen after gemcitabine-based therapy for patients unresectable or recurrent pancreatic cancer. However, there are limited clinical data on its efficacy safety in the real-world. We therefore initiated retrospective prospective observational study (NAPOLEON-2). The results of part were reported herein. In this study, we evaluated 161 consecutive who received NFF as second-or-later-line regimen. main...
721 Background: Nanoliposomal irinotecan (NAL-IRI) and fluorouracil with folinic acid (NFF) is the standard regimen after gemcitabine-based therapy for unresectable or recurrent pancreatic cancer (urPC). However, we have almost no prospective data on its efficacy safety in real-world, so conducted this study to investigate them both retrospectively prospectively (NAPOLEON-2 study). We previously reported retrospective ASCO-GI 2023, here report final results of part. Methods: collected urPC...
762 Background: Nanoliposomal irinotecan and fluorouracil with folinic acid (NFF) is a standard regimen after gemcitabine-based chemotherapy (CTx) for unresectable or recurrent pancreatic cancer (urPC) patients. Neutropenia caused by systemic CTx has been reported to be prognostic marker in several cancers, however, the relationship between neutropenia efficacy of NFF urPC patients unknown. Therefore, we initiated prospective observational study investigate whether can real-world (NN-2401),...
Abstract There are limited absolute biomarkers for determining the prognosis before first- and second-line palliative chemotherapy in unresectable pancreatic cancer (urPC) patients. To find best prognostic inflammatory marker, we investigated relationships between overall survival (OS) six markers; C-reactive protein/albumin ratio (CAR), neutrophil–lymphocyte (NLR), nutrition index (PNI), platelet–lymphocyte (PLR), Glasgow score (GPS), (PI). We examined 255 patients who received gemcitabine...
Abstract The relationship between nanoliposomal irinotecan/fluorouracil/leucovorin (NFF) treatment outcomes and neutropenia in patients with pancreatic cancer has not been thoroughly examined. Thus, we conducted a retrospective analysis of data from who were treated NFF to investigate this relationship. Neutropenia was assessed according the Common Terminology Criteria for Adverse Events across three cutoffs: A (grade 0 versus grade 1–4), B (grades 0–1 2–4), C 0–2 3–4). primary endpoint...
Background: Relationships between cancer onset, progression, and inflammation have been reported; yet, the significance of inflammatory markers before after treatment with nanoliposomal irinotecan fluorouracil folic acid (NFF) is unclear. Objectives: We aimed to (1) investigate whether worsening associated disease progression it can be used as a biomarker by comparing NFF (2) verify which superior biomarker. Design: This was preplanned analysis retrospective cohort NAPOLEON-2 study,...
Abstract Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis was conducted using clinical data of Japanese GnP FOLFIRINOX obtained from a multicenter study (NAPOLEON study). A Cox proportional hazards model used to identify independent prognostic factors. predict 6–, 12–, and 18–month probabilities generated,...
Abstract First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line role combination in clinical practice is still unknown. Data was gathered from 14 hospitals Kyushu area Japan December 2013 to March 2017. The median overall survival (mOS) treatment contrasted between who received (CT group) those best supportive care (BSC group). Furthermore, mOS compared mono CT...
Abstract This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated gemcitabine plus nab–paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective studies included 318 receiving nanoliposomal irinotecan + 5-fluorouracil/folinic acid (NFF) (n = 102), S-1 57), or FOLFIRINOX 14) as treatment. Median overall survival (OS) in the NFF group was 9.08 months, significantly better than (4.90 P 0.002). had a...
Recent advances in chemotherapy have made significant progress conversion surgery (CS) for unresectable pancreatic cancer (uPC). However, the success rate and efficacy of CS not been fully demonstrated patients with uPC treated FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP).We retrospectively reviewed records 318 who received FFX GnP as first-line chemotherapy. The group, defined undergoing complete resection after chemotherapy, was analyzed, compared non-CS group; then,...
FOLFIRINOX (FFX, a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) gemcitabine plus nab-paclitaxel (GnP) have been used as standard, first-line treatments for advanced pancreatic cancer. However, no study has compared the efficacy 2 regimens. This retrospectively safety regimens in patients with locally cancer.We reviewed records cancer who started FFX or GnP chemotherapy part multicenter retrospective unresectable treated (NAPOLEON study).Sixteen 63 were FFX, other 47...
Abiraterone acetate and docetaxel are promising treatment options for metastatic castration-resistant prostate cancer patients. However, the optimal sequencing of these agents is unclear, no previous reports discuss Japanese The purpose this analysis to reveal outcomes patients treated with abiraterone followed by docetaxel. We retrospectively reviewed Phase 1 2 trials until disease progression subsequently primary outcome measure was rates prostate-specific antigen declines ≧30 ≧50%,...
706 Background: Nanoliposomal irinotecan (NAL-IRI) and fluorouracil with folinic acid (NFF) is the standard regimen after gemcitabine-based therapy for unresectable or recurrent pancreatic cancer (urPC). We conducted this NAPOLEON-2 study to investigate efficacy safety of NFF explore predictive prognostic factors, retrospectively prospectively, in real world. previously reported interim analysis retrospective data 6 months end collection ( Ann Oncol. 2022;33(suppl 4): S289-S290). Here, we...
Background/Aim: The aim of the study was to evaluate gemcitabine plus nanoparticle albumin-bound paclitaxel (GnP) and FOLFIRINOX for recurrent pancreatic cancer (rPC) after resection. Patients Methods: Forty-four patients with rPC 211 de novo metastatic (mPC) who received GnP or as first-line chemotherapy were retrospectively analyzed. Results: On crude analysis, median overall survival (OS) significantly longer in group than mPC (14.0 vs. 10.6 months, respectively; p=0.02). However,...
<title>Abstract</title> Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard regimen after gemcitabine-based therapy for patients unresectable or recurrent pancreatic cancer. However, there are limited clinical data on its efficacy safety in the real-world. We therefore initiated retrospective prospective observational study (NAPOLEON-2). The results of part were reported herein. In this study, we evaluated 161 consecutive who received NFF as second-or-later-line...
Introduction: Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improve overall survival (OS) progression-free (PFS) in patients with pancreatic cancer, compared gemcitabine (GEM). However, whether PFS is a surrogate marker of OS cancer chemotherapy focusing on FOLFIRINOX or GEM plus nab-paclitaxel remains unknown. We aimed to verify can be prognosis prediction. Methods: This was an integrated analysis the NAPOLEON study retrospective cohort NAPOLEON-2 study—a multicenter...
661 Background: Gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX) have been established as standard first-line combination chemotherapy (CTx) for patients with metastatic pancreatic cancer (MPC). However, the efficacy of second-line CTx significance in clinical practice are unclear. We therefore investigated MPC. Methods: Data were collected from CTx-naive MPC treated at 14 hospitals Kyushu area Japan December 2013 to June 2018. The median overall survival (mOS) treatment was...